Emcure Pharmaceuticals Limited

EMCURE.NS·NSE·Healthcare
Compare
2,245.00+84.60 (+3.92%)today
At close: Nov 5, 3:29 PM IST · May be delayed up to 15 min · INR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close2,160.40
Open2,179.00
Day range2,143.002,266.40
52-week range1,312.302,266.40
Off day high−0.94%
Off 52-week high−0.94%
Volume535.85K
Avg. volume (3M)179.82K
Market cap425.90B
EPS (TTM)57.63
Forward P/E27.93
P/E ratio (TTM)38.96
Dividend yield0.17% (3.60)
Beta (5Y)0.00
Shares outstanding189.71M
Short interest—
Earnings dateMay 22, 2025
Analyst target2,229.38
Profit margin10.44%

Against its peers

Compare in full ›
EMCURE.NS GRANULES.BO 003220.KS TAK TEVA MOREPENLAB.NS
Market cap 425.90B 192.80B 172.75B 67.28B 48.83B 53.21B
P/E (TTM) 39.0 35.3 — 300.9 97.3 28.3
Forward P/E 27.9 26.5 — 39.7 13.4 —
Price/book 8.0 4.8 — 1.4 6.1 3.9
Dividend yield 0.17% 0.26% 3.11% 2.93% — 0.20%
1-year change +58.97% +0.63% −38.51% +54.40% +71.10% +113.46%
Today +3.92% −0.01% +0.37% +1.49% −0.14% −4.17%

The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.

MarketScreener·Positive

Gilead Sciences, Inc. Expands Royalty-Free Voluntary Licensing Agreements For Lenacapavir With Dr. Reddy?s Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma For Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero And Mylan Laboratories Limited

Gilead Sciences, Inc. announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV... announced that it has expanded the scope of…

From the 4Search news index, newest first.

In the news

6mentions in 30 days
6with it in the headline
Mixedsentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance